Rabella Et Al 2020 PDF
Rabella Et Al 2020 PDF
Rabella Et Al 2020 PDF
The in vitro susceptibility to acyclovir of 204 herpes simplex virus isolates from 165 immunocompromised
patients treated at our hospital was determined by the cytopathic effect reduction assay. Approximately 95%
of herpes simplex virus 1 and 73% of herpes simplex virus 2 isolates were inhibited by acyclovir at concen-
trations of !2 mg/mL. From 8 patients (5%), an isolate with low susceptibility to acyclovir (50% inhibitory
dose, 13 mg/mL) was recovered. Medical records of 83 patients were reviewed. Lesions resolved in most of the
patients, independent of treatment. Treatment failures were not always associated with isolation of an in
vitro–resistant virus. On the contrary, when a virus with low susceptibility to acyclovir was isolated, resolution
of the lesion was the rule. In 9 of 10 patients with subsequent recurrent episodes of disease, the susceptibility
of the viruses isolated was similar to that of the first episode. Routine susceptibility testing in our geographic
area is not encouraged because of the low incidence of acyclovir-resistant herpes simplex viruses.
Infections caused by herpes simplex virus (HSV) are a prolonged Acv therapy; strains of HSV that are less
major cause of morbidity in immunosuppressed hosts, susceptible or resistant to Acv have occasionally been
such as patients who are positive for HIV or are un- recovered from these patients [3]. Otherwise, in im-
dergoing organ transplantation. Acyclovir (Acv) is the munocompromised patients who receive Acv for the
drug of choice for treatment of these patients. Admin- management of acute HSV disease, the incidence of
istered orally or intravenously, it decreases pain and resistance is extremely low. In addition, Acv-resistant
viral shedding and accelerates healing [1]. Topical ther- strains of HSV have rarely been isolated from immu-
apy can also be useful for these patients, although it is nocompetent patients [4].
not as effective [2]. Mucocutaneous HSV infections are The use of susceptibility testing could help improve
usually self-limited in the immunocompetent host. Be- the management of patients with herpesvirus disease
cause immunosuppressed patients cannot depend on who are unresponsive to standard regimens of Acv. Pa-
their immune system to eliminate the virus, infection tients whose lesions persist or worsen while they are
can result in extensive and persistent ulcerative disease
receiving Acv therapy could benefit from susceptibility
with continuous viral shedding and lack of response to
studies. In such cases, knowledge of a strain’s in vitro
susceptibility to Acv would be useful for the selection
of alternative antiviral therapy [5–7], which might in-
Received 9 July 2001; revised 27 November 2001; electronically published 11
March 2002. volve increasing the dose of oral Acv or changing to
Financial support: Partially support from the Fondo de Investigaciones Sanitarias high-dose continuous infusion of Acv (for those pa-
de la Seguridad Social (FISS), Spain (grant 93/0405). Spanish Ministerio de
Educación y Cultura (grant AP94 35775298 [to M.O.]). tients who do not respond to standard regimens of Acv)
Reprints or correspondence: Dr. Núria Rabella, Av. Sant Antoni Ma Claret 167, [8, 9]. To determine the susceptibility of HSV to Acv,
08025 Barcelona, Spain ([email protected]). various tests have been designed. The most frequently
Clinical Infectious Diseases 2002; 34:1055–60
used tests are the plaque reduction assay (PRA), the
2002 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2002/3408-0004$03.00 viral cytopathic effect reduction assay (CRA), the dye-
Table 2. Susceptibility of herpes simplex virus (HSV) isolates recovered from 2 patients with persistent lesions.
NOTE. Acv, acyclovir; ID50, drug concentration causing a 50% reduction in viral cytopathic effect; ID90, drug concentration causing a 90% reduction in viral
cytopathic effect.
a
Duration of therapy is measured from the date the specimen was obtained. The oral dosage of Acv was 200 mg given 5 times per day.
b
Because of the persistence of lesions, the dosage of Acv was increased to 800 mg given 5 times per day until lesions resolved.
NOTE. Acv, acyclovir; ID50, drug concentration causing a 50% reduction in viral cytopathic effect; ID90, drug concentration causing a 90% reduction in viral
cytopathic effect; TP, transplantation.
a
The oral dosage of Acv was 200 mg given 5 times per day for 10 days, and the intravenous dosage of Acv was 400 mg given every 8 h for 10 days.
b
The lesions that yielded these isolates resolved with standard regimens of oral Acv therapy.
c
Two episodes separated by 17 months.
and Enders [22] for the in vitro study of the susceptibility of Acv ID50 values of 12 mg/mL. Swierkosz and Biron [32] pro-
cells to interferon. De Clercq et al. [23] and DeClerq [24] used posed that when the DUA is used to study susceptibility, the
the CRA to study the susceptibility of HSV to antivirals. The ID50 value denoting resistance would be 13 mg/mL. In our study,
addition of the vital dye neutral red to the drug-treated, virus- 9 (4%) of 204 virus strains studied (recovered from 5% of the
infected cultures permits automated reading. This method was patients), were resistant at Acv ID50 values of 3 mg/mL.
named the “dye-uptake method.” McLaren et al. [25] adapted It should be noted that, although a low susceptibility to Acv
the DUA method for the study of HSV susceptibility to acy- in vitro was detected in the HSV strains in our study, resistance
clovir. The DUA is equivalent to the CRA, the only difference did not seem to be the major cause of treatment failure, because
being the reading method, and the ID50 values determined by other factors, such as the patient’s immunologic status, may
the CRA and the DUA are comparable, if the optimal condi- have contributed to the poor clinical response. Medical records
tions for both assays are applied [26]. were available for 10 patients infected with strains of HSV for
In our study, we used the CRA, with Vero cells, to test all which the Acv ID50 was 12 mg/mL at presentation. The lesions
isolates. This assay is based on measurements of the inhibition of all of these 10 patients resolved, with or without Acv treat-
of the cytopathic effect and provides a simple determination ment (table 3).
of Acv susceptibility [27]. Using this assay, we found that re- On the other hand, persistence of lesions in spite of therapy
peated testing of several specimens of the same lesion revealed was unrelated to the Acv ID50 of the infecting strain. Testing
similar susceptibilities (table 1), which indicates that the assay results for the 2 patients (patients 45 and 5) whose lesions
has an acceptable degree of reproducibility. persisted and then finally resolved (table 2) show that all isolates
Our results show that the mean ID50 value for HSV-1 (0.615 were susceptible to Acv. Patient 45 received a standard regimen
mg/mL) is almost 3 times lower than that for HSV-2 (1.698 mg/ of Acv, and the HSV isolate was susceptible in vitro. During
mL). These differences and the overlapping of values for the 2 treatment, a new lesion appeared at another site (probably be-
types of viruses confirm previous observations [27–30]. cause of autoinoculation), and, from this lesion, we were also
There is no consensus of opinion regarding which level of able to isolate a strain of HSV that was susceptible to Acv. The
in vitro susceptibility indicates a resistant virus, but most in- lesions resolved completely after treatment with higher doses
vestigators agree that Acv-resistant isolates are usually suscep- of Acv. In patient 5, the lesion did not resolve until the patient
tible to Acv concentrations of 12 mg/mL. However, Chatis and received Acv (table 2).
Crumpacker [31] pointed out that an Acv ID50 value of 12 mg/ HSV infections are usually mild and self-limited. Cell-me-
mL is unusually high for the definition of resistance to Acv, diated immunity plays a significant role in the eradication of
and use of this value could underestimate the real incidence of HSV disease. The great variability in the abilities of immu-
resistance. We detected 26 HSV strains (6 HSV-1 strains and nosuppressed patients to control viral infections is a major
20 HSV-2 strains)—or 13% of the strains isolated—that had confounding factor in efficacy testing of any antiviral therapy.
Episode
(days since Acv ID50
previous of isolate, Type of
Patient Isolate episode) mg/mL Acv therapya Lesion outcome
1 HSV-1 1 (0) 0.397 Oral Resolution
2 (63) 0.199 Oral Resolution
2 HSV-1 1 (0) 0.167 Intravenous Resolution
2 (43) 0.281 Topical Resolution
3 (350) 0.084 Intravenous, oral Resolution
4b HSV-2 1 (0) 0.941 Topical Resolution
HSV-1 2 (146) 0.792 Topical Resolution
NOTE. Acv, acyclovir; ID50, drug concentration causing a 50% reduction in viral cytopathic
effect.
a
The oral dosage of Acv was 200 mg given 5 times per day for 10 days, and the intravenous
dosage of Acv was 400 mg given every 8 h for 10 days.
b
Recurrence with different virus type at another site.
c
For episodes 1, 2, and 3, isolates were recovered from specimens obtained from the same
lesion on different days; episode 4 was a recurrence.
d
Patient died before completion of treatment.
Favorable responses were observed in most of our patients poor absorption of the drug, and interaction between drugs,
regardless of therapy. Six episodes of disease resolved without should be taken into account before resistance to antiviral ther-
treatment. Moreover, in the 3 episodes for which the HSV apy is suspected.
isolates were susceptible at Acv ID50 values of 13 mg/mL and After primary infection, HSV remains latent in the organism
for which the patients were treated with Acv, the lesions re- for life, and, from time to time, the virus reactivates and pro-
solved with the use of standard regimens of the antiviral agent, duces a recurrent disease. Recurrences probably reflect the virus
a result that reinforces the finding that most HSV infections that caused the primary infection [19]. During follow-up, a
are self-limited, independent of therapy. total of 15 recurrences of disease were recorded. All but 1 of
Refractory disease due to HSV in these patients could be the HSV isolates were clearly susceptible to Acv in vitro, a
related to circumstances other than in vitro susceptibility. The finding that shows that the appearance of resistance is very
description of HSV as resistant at Acv ID50 values of 13 mg/ infrequent when Acv is used at standard dosages to manage
mL is probably appropriate, on the basis of multiple studies acute infections.
[32–36], other factors, such as incomplete adherence to therapy, To summarize, in 5% of the patients in our study (4 of 83),